Skip to main content

Table 1 Six studies pertaining to CD34+ cells in t-AML and normal controls.

From: Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles

 

GSE24006

GSE30377

GSE17054

E-TABM-978

Qian

GSE23025

sum

Journal

leukemia

Nat. Med

PNAS

Cancer Cell

PNAS

Cancer Cell

 

year

2011

2011

2009

2011

2002

2011

 

Platform

Hgu133+2

Hgu133a

Hgu133+2

HsHT-12

Hgu95av2

Hgu133+2

 

PMID

21177505

21873988

19218430

21251617

12417757

22094254

 

t-MDS/tAML CD34+ progenitor (BM), -5/del5q

    

4

1

28

t-MDS/tAML CD34+ progenitor (BM), -7/del7q

    

3

3

 

t-MDS/tAML CD34+ progenitor (BM), -5/del5q or -7/del7q

    

2

  

t-MDS/tAML CD34+ progenitor (BM), normal 5 and normal 7

    

7

8

 

normal progenitor (CD34+, BM)

    

2*

 

24

normal HSC+ (CD34+CD133+, BM)

       

normal HSC+ (Lin-CD34+CD38-, PB)

 

3

     

normal HSC+ (Lin-CD34+CD38loCD36-, PB)

 

3

     

normal HSC+ (Lin-CD34+CD38-CD90+, PB or BM)

  

4

    

normal HSC+ (Lin-CD34+CD38-CD90+CD45RA-, PB)

3

      

normal HSC+ (Lin-D34+CD38-CD90+CD45RA-, BM)

4

  

5

   
  1. * Among 3 author collected samples, the one from a patient with breast cancer was excluded and the other two were included.
  2. PBSC: peripheral blood stem cells; BM: bone marrow samples
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us